1 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Anwar Iqbal, Ph.D., FFACMG�Professor, Pathology Department�Director, Microarray CGH Lab

Optical Genome Mapping – Enables Next-Generation Cytogenetics

2 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

I do not have any disclosures to declare

Full Disclosure

3 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Goals & Learning Objectives

GOALS

​

  • Discuss concordance and discordance of OGM with standard of care approaches in constitutional disorders and cancers

​

  • Discuss integration of OGM as an alternate cytogenetic, FISH and Microarray method for patient care

​

  • Discuss the cost and technical knowhow needed for OGM as cytogenetic diagnostic assay

LEARNING OBJECTIVES

​

  • Understand the basic principles of Optical Genome Mapping (OGM)

​

  • Understand the strengths and limitations of OGM in the diagnosis of genomic abnormalities

​

  • Compare OGM to current diagnostic standard of care tests

4 of 35

4

Human Genome Project

Sequence of the Human Genome Blueprint (RP11-Library)

​

April 14, 2003

Optical Genome Mapping

​

1960

Chromosome Diagnosis

Testing

FISH

1980

30 years

CMA Testing

Postnatal

​

2010

2012+

Prenatal CMA

2024-2026

R &D ERA

Tier 1

Tier 1

​

NYS Approved LDT Assay

Constitutional

Cancer microarray

Recommended

AI Journey at URMC- April 2006 - current

NYS Approved LDT Assay –Cancer

Clinical Cytogenomic timeline

5 of 35

CMA (3-5 Days)

Chromosome, FISH, and CMA Workflow

6 of 35

6

​

Chromosome Assay

​

  • Most cost- effective whole genome platform with resolution (5Mb-10Mb)

​

  • Extremely difficult or impossible to detect >500 micro deletion /duplication syndromes below the chromosome assay resolution

​

​

FISH Assay

​

  • Highly sensitive – Targeted (50Kb-150kb resolution)

​

  • Need to know the lesion before testing for selection of target probe

​

  • Variable sensitivity in constitutional genetic syndromes – Example: DGS

Chromosome/FISH – Advantages and Limitations

7 of 35

7

Advantages of CMA

​

  • Higher yield 15% to >20% than G- Banded karyotype - 3%

​

  • More precise breakpoints and gene content

​

  • More sensitive in detecting Insertional Translocations (Six fold)

​

  • Better in detecting partial and full moles

​

Limitations of CMA

​

  • Cannot detect balance rearrangements (translocations, inversions)

​

  • Cannot define orientation of the CNVs (insertion, Duplications)

​

CMA – Advantages & Limitations

8 of 35

8

Optical Genome Mapping (OGM) - Overview

9 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Sample-To-Report OGM Workflow

Slide courtesy of Alex Hastie, Bionano

10 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Linearization Of Native DNA

nanochannels live video in SAPHYR

OGM WORKFLOW STEP 3

Slide courtesy of Alex Hastie, Bionano

11 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Circos Plot Details

CNV track

SV track

deletions, insertions, inversions, duplications

Idiogram

Translocations

hg38

OGM WORKFLOW STEP 7

12 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Structural Variants Calling - OGM

For example

Deletion 5p-

For example

KMT2A tandem duplication

For example

Inversion 16q

(CBFB)

For example

t(9;22) BCR::ABL

For example

KMT2A insertion

13 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Normal: 

Male: ogm (X,Y)x1(1-22)x2

 

Female: ogm (X,1-22)x2

 

 

Abnormal:

ogm (21,22)x3

​

ogm[GRCh38] 22q11.21q11.23(21312519_23509455)x1

​

ogm[GRCh38] 2q31.2q36.1(178041887_221245057)x3, 43Mb gain�ins(2;14)(q36.1q31.2;q32.33)(178041887_221245057;105153086)

​

 

OGM Nomenclature

14 of 35

Example Cases

15 of 35

  • 41 years, female
  • Pregnancy loss
  • Karyotype: 48,XY,+21,+22[6]/46,XX[14]
  • OGM: ogm (21,22)x3

Product of conception - Trisomy 21 and 22

16 of 35

  • 35 years, female
  • Amniotic Fluid
  • Abnormal US
  • Karyotype: 69,XXX
  • OGM: ogm (X,1-22)x3

The split in the BAF track (Purple) - Triploid

Amniotic Fluid Cultured Cells - Triploid

17 of 35

  • 10 years, Male
  • Peripheral Blood
  • Autistic Disorder and ADHD
  • Microarray:

arr[hg19/GRCh37] 22q11.21q11.23(21,922,619-23,654,064)x1

  • OGM:

ogm[GRCh38] 22q11.21q11.23(21312519_23509455)x1

DiGeorge (22q11.2) Microdeletion, 1.7 Mb (URMC_LDT_8)

18 of 35

  • 20 years Female
  • Gestational age 19 weeks and 1 day
  • Abnormal ultrasound: left-sided congenital diaphragmatic hernia (CDH), absent nasal bone, dilated third ventricle and severe pulmonary hypoplasia.

​

Amniotic Fluid - Direct CMA

19 of 35

CMA (direct) - Chromosome (culture) - FISH

​

CMA does not provide location or orientation of CNV

arr[GRCh37/hg19] 2q31.2q36.1(178906614_222109777)x3 43Mb gain

Karyotype does not provide origin of extra material, orientation, or chr14 breakpoint

​

FISH does not provide chr14 breakpoint

46,XY,der(14)?ins(14;2)(?q32;?q31.2q36.1)

ish der(14)ins(14;2)(?q32;?q36.1q31.2)

20 of 35

Unbalanced Insertion 2;14

Duplication 2q

Breakpoint at 14q32.33 (JAG2, between exon 5 and 6)

ogm[GRCh38] 2q31.2q36.1(178041887_221245057)x3, 43Mb gain�ins(2;14)(q36.1q31.2;q32.33)(178041887_221245057;105153086)

OGM – validation study sample

21 of 35

  • JAG2: Muscular dystrophy, limb-girdle, autosomal recessive 27
  • Pathophysiology: JAG2 encodes the Jagged2 protein, a Notch signaling ligand critical for embryonic development, cell fate determination, and tissue differentiation. Disruption may impact myogenesis, resulting in muscular dystrophy.
  • Genetic counseling: Parental testing to assess inheritance, clinical features can overlap with other muscular dystrophies; whole-exome sequencing is often required to identify the pathogenic variant.

JAG2 disease association and Genetic counseling

22 of 35

  • 04 years Female
  • Developmental delay particularly in language, microcephaly, slight bilateral epicanthal folds, nose slightly upturned with thin upper lip, slightly upturned corners of the mouth, very mild micrognathia, and seizure disorder
  • CT scan of head and MRI of brain were both normal
  • Karyotype: 46,XX,inv(2)(p23q31)
  • aCGH: Normal, arr(1-22,X)x2
  • TAT- Standard Of Care
  • Culture & Karyotyping: 7 Days
  • aCGH: 7 Days

​

TAT- Optical Genome Mapping (Cultured cells)

5 days

​

​

Postnatal Case (URMC_LDT_40)-LCL

23 of 35

Postnatal Case (URMC_LDT_40)-LCL

24 of 35

�ogm[GRCh38] inv(2)(p22.1;q24.3)(40,887,850~40,892,642;166,020,084~166,023,624)[VAF:0.52]

25 of 35

Breakpoint at 2q24.3 (SCN1A, between exon 19 and 20)

ogm[GRCh38] inv(2)(p22.1;q24.3)(40,887,850~40,892,642;166,020,084~166,023,624)[VAF:0.52]

26 of 35

  • SCN1A: Autosomal dominant, Dravet Syndrome, Developmental and epileptic encephalopathy 6B/non-Dravet, Febrile seizures-familial-3A, Generalized epilepsy with febrile seizures plus-type 2.
  • Pathophysiology: SCN1A encodes the alpha-subunit of the Nav1.1 voltage-gated sodium channel, highly expressed in the central nervous system and is essential for neuronal excitability and inhibitory signaling. An inversion within this gene may disrupts its structure, typically causing a loss-of-function through haploinsufficiency.
  • Genetic counseling: Parental testing to assess inheritance, recurrence low ~1% (de novo), high up to 50% (inherited). Potential parental mosaicism (7-13%)
  • Anti seizure medication

SCN1A disease association and Genetic counseling

27 of 35

  • 30 years male
  • Couple with recurrent pregnancy loss
  • Obstructive hydrocephalus, anxiety disorder, impaired cognition
  • Karyotype: 46,XY

RPL Case (RSA-009)-Blood

28 of 35

FISH: 1ptel (SO), Xptel/Yptel (SG)

Xptel

der(Y)ins(Y;1)(p11.2;q44q44)

1qtel

der(1)ins(Y;1)(p11.2;q44q44)

�ogm[GRCh38] der(Y)ins(Y;1)(p11.2;q44q44)(9,570,015~9,579,041;�248,699,354~248,708,380_248429145~248435480)[VAF:0.59]

​

29 of 35

  • OR14I1 (OMIM-618516): olfactory receptor family 14 subfamily I member 1
  • Yp11.2 insertion involving disruption of OR14I1 is likely of low clinical impact at gene level
  • Primary significance related to Y chromosome structural rearrangement and reproductive risk assessment (PMID: 38524217)

​

Yp11.2 insertion, disease association and Genetic counseling

30 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Conclusions:

  • Twenty-three couples with ITs underwent preimplantation genetic testing for structural chromosomal rearrangements (PGT-SR)

​

  • The chance of identifying normal or balanced and mosaic blastocysts per mature oocytes in patients with ITs are 16.6% (67/404)

​

  • Greater IT complexity results in fewer transferable embryos

​

  • For simple interchromosome ITs, female carriers and those with higher haploid autosomal length values have a higher risk of producing embryos with unbalanced rearrangement

PMID: 38524217

31 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Variant Classes Detection

By Platform Type

Slide courtesy of Alka Chaubey, Bionano

32 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

  1. OGM as a valid alternative for current SOC in cytogenetic diagnostics laboratories
  2. OGM was able to detect an unprecedentedly wide range of structural abnormalities in one assay
  3. OGM showed 97%-99% complete concordance with commonly used samples (blood, BM, cultured cells)
  4. Limitations of OGM observed fall within complex genomic regions, or very small aberrations (SNVs).
  5. NYS approved OGM assay for both constitutional (germline) and Cancer (Somatic) at URMC for Clinical Testing

​

Summary

33 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

NYS LDT Approval for Clinical Testing

(Timeline- 2024-2026)

34 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

Acknowledgements

Department of Pathology and Laboratory Medicine

​

​

​

DNA Microarray CGH & Cytogenetics Team

​

​

​

​

​

​

​

​

35 of 35

M. Anwar Iqbal, DNA Microarray CGH Lab

THANK YOU

❓